# US 2024/0393320 A1 · Platforms for drug tests against synucleinopathy using human brain organoids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0393320 A1
- Document ID: US20240393320A1
- Status: Published application
- Kind: A1
- Application number: 18/693,722
- Filed: 2022-09-21
- Published: 2024-11-28
- Earliest claimed: 2021-09-21
- Assignees: Okinawa Institute of Science and Technology School Corporation
- Applicants: Okinawa Institute of Science and Technology School Corporation
- Inventors: Junghyun JO; Hoang-Dai TRAN; Gordon William ARBUTHNOTT
- Web page: https://patentgrep.com/patent/US20240393320A1

## CPC

- G01N 33/5058: {Neurological cells}
- C12N 5/0619: {Neurons}
- G01N 33/5038: {involving detection of metabolites per se}
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2506/02: from embryonic cells
- C12N 2513/00: 3D culture
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides human striatal-like organoid (hSLO) similar to a huma striatum, a fusion organoid of hSLO and human midbrain-like organoid (hMLO) having functional connections between the hSLO and hMLO, and method of testing drugs using the organoids culture platform.

## Claims

### Claim 1

A method of culturing an embryoid body (EB) such as a human embryoid body, comprising:
culturing an EB in a first culture medium containing a first factor, wherein the first factor comprises a TGF-β signaling pathway inhibitor and/or Wnt inhibitor such as GSK inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
culturing the obtained EB in a second culture medium containing a second factor, wherein the second factor comprises a Wnt inhibitor, patterning factors for sonic hedgehog pathway activation, and activin without first factors to obtain an LGE neurospheres.

### Claim 3 (depends on 2)

The method of claim 2, further comprising:
culturing the obtained EB in a third culture medium containing a third factor, wherein the third factor comprises brain-derived neurotrophic factor (BDNF) and/or ascorbic acid without the first and second factors to obtain an organoid such as a human striatal-like organoid.

### Claim 4 (depends on 3)

The method of claim 3, wherein the obtained organoid comprising one or more markers of a mature medium spiny neuron (MSN).

### Claim 5 (depends on 4)

The method of claim 4, wherein the obtained organoid comprising D1 and/or D2 MSN.

### Claim 6 (depends on 5)

The method of claim 5, wherein the obtained organoid expresses at least one or all of interneuron makers such as TH, cholinergic neuron and serotonin neuron markers such as CHAT and 5-HT, glial cell markers such as MBP, and GFAP.

### Claim 7 (depends on 4, 5, 6)

The method of any one of claims 4 to 6, wherein the organoid has 1 mm or more in major axis diameter or in diameter, preferably 1 mm to 2 mm in major axis diameter or in diameter.

### Claim 8

An isolated organoid comprising: a mature medium spiny neuron (MSN) expressing one or more markers of a mature MSN.

### Claim 9 (depends on 8)

The isolated organoid of claim 8, wherein 50% or more of the cells contained in the organoid are DARPP32 positive and GABA positive.

### Claim 10 (depends on 8, 9)

The isolated organoid of claim 8 or 9, comprising D1 and/or D2 MSN.

### Claim 11 (depends on 8, 9, 10)

The isolated organoid of any one of claims 8 to 10, wherein the organoid expresses at least one or all of interneuron makers, cholinergic neuron markers, and serotonin neuron markers.

### Claim 12 (depends on 8, 9, 10, 11)

The isolated organoid of any one of claims 8 to 11, wherein the organoid has 1 mm or more in major axis diameter or in diameter.

### Claim 13 (depends on 8, 9, 10, 11, 12)

A method of producing an organoid, comprising:
providing an organoid of any one of claims 8 to 12 (a first organoid), and a second organoid comprising a dopaminergic (DA) neuron, and contacting the first organoid and the second organoid to obtain a fusion organoid of the first organoid and the second organoid, wherein a dopaminergic neuron in the second organoid has projection that reaches the first organoid, and a GABAergic MSN in the first organoid has projection that reaches the second organoid.

### Claim 14 (depends on 8, 9, 10, 11, 12)

A fusion organoid of the first organoid of any one of claims 8 to 12 and the second organoid comprising a dopaminergic (DA) neuron, wherein a dopaminergic neuron in the second organoid has projection that reaches the first organoid, and a GABAergic MSN in the first organoid has projection that reaches the second organoid.

### Claim 15 (depends on 14)

The fusion organoid of claim 14, wherein the cells included in the fusion organoid comprises a DA neuron having α-syn aggregation.

### Claim 16 (depends on 14, 15)

A method of testing a candidate drug, comprising:
contacting the candidate drug and the fusion organoid of claim 14 or 15,
observing α-synuclein aggregation in a DA neuron, and
selecting the candidate drug that decreases α-syn aggregation, compared to a negative control.

### Claim 17 (depends on 16)

The method of claim 16, wherein SNCA is overexpressed in at least a DA neuron or all cells in the second organoid entity or the organoid.
